Polar Capital Global Healthcare Trust (LSE:PCGH) Research & Development: £0.00 Mil (TTM As of Mar. 2026)


LSE:PCGH Polar Capital Global Healthcare Trust PLC LSE:PCGH
54 GF Score
Price £4.38
GF Value £9.07
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Polar Capital Global Healthcare Trust Research & Development?

Polar Capital Global Healthcare Trust LSE:PCGH +1.86% 54 Research & Development is £0.00 Mil as of Mar. 2026. GuruFocus rates LSE:PCGH with a GF Score™ of 54/100 and a GF Value™ of £9.07 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Polar Capital Global Healthcare Trust's Research & Development for the six months ended in Mar. 2026 was £0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was £0.00 Mil.

Polar Capital Global Healthcare Trust  (LSE:PCGH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Polar Capital Global Healthcare Trust Research & Development Related Terms

Polar Capital Global Healthcare Trust Research & Development Historical Data

* Premium members only.

The historical data trend for Polar Capital Global Healthcare Trust's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Polar Capital Global Healthcare Trust Research & Development Chart

Polar Capital Global Healthcare Trust Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Polar Capital Global Healthcare Trust Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LSE:PCGH
54GF Score
Polar Capital Global Healthcare Trust PLC LSE:PCGH
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Polar Capital Global Healthcare Trust Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of £0.00 Mil mean?
Polar Capital Global Healthcare Trust (LSE:PCGH) has a Research & Development of £0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Polar Capital Global Healthcare Trust and its competitors.
Is Polar Capital Global Healthcare Trust's Research & Development too high?
Polar Capital Global Healthcare Trust's current Research & Development is £0.00 Mil. Overall, Polar Capital Global Healthcare Trust has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Polar Capital Global Healthcare Trust's Research & Development compare to BLK and BX?
Polar Capital Global Healthcare Trust's Research & Development of £0.00 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Asset Management company?
A good Research & Development depends on the Asset Management industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Polar Capital Global Healthcare Trust and its competitors. Polar Capital Global Healthcare Trust's current Research & Development is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polar Capital Global Healthcare Trust stock overvalued right now?
Based on GuruFocus' analysis, Polar Capital Global Healthcare Trust (LSE:PCGH) is currently considered Significantly Undervalued. The stock's GF Value™ is £9.07, compared to a current price of £4.38 — trading 51.7% below its estimated fair value. The current Research & Development is £0.00 Mil. Polar Capital Global Healthcare Trust's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Polar Capital Global Healthcare Trust (LSE:PCGH), the current Research & Development is £0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Polar Capital Global Healthcare Trust (LSE:PCGH) Overvalued in 2026?

Based on GuruFocus' analysis, Polar Capital Global Healthcare Trust stock appears to be undervalued. The current stock price of £4.38 is trading 51.7% below its estimated GF Value™ of £9.07. GuruFocus considers Polar Capital Global Healthcare Trust to be Significantly Undervalued.

Key valuation signals for LSE:PCGH:

  • Research & Development: £0.00 Mil
  • GF Value™: £9.07 vs. price of £4.38 (51.7% below fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the LSE:PCGH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Polar Capital Global Healthcare Trust Business Description

Address 16 Palace Street, London, GBR, SW1E 5JD
Polar Capital Global Healthcare Trust PLC is a United Kingdom-based investment trust company. The company's investment objective is the generation of capital growth through investments in a portfolio of healthcare stocks. The purpose of the company is to provide an investment vehicle for investors which aims to deliver long term capital growth to shareholders from a range of diversified healthcare stocks.
54GF Score

Get the complete analysis for LSE:PCGH

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£4.38
Price
£9.07
GF Value